Latent carcinogenicity of early-life exposure to dichloroacetic acid in mice. (25th April 2015)

• Record Type: Journal Article
• Authors: Wood, Charles E.; Hester, Susan D.; Chorley, Brian N.; Carswell, Gleta; George, Michael H.; Ward, William; Vallanat, Beena; Ren, Hongzu; Fisher, Anna; Lake, April D.; Okerberg, Carlin V.; Gaillard, Elias T.; Moore, Tanya M.; Deangelo, Anthony B.
• Is Part Of: Carcinogenesis. Volume 36:Number 7(2015:Jul.)
• Page Start: 782
• Page End: 791
• Publication Date: 2015-04-25
• Subjects: Carcinogenesis -- Periodicals; Cancer -- Genetic aspects -- Periodicals; Cancer -- Prevention -- Periodicals; Cancer -- Periodicals; 616.994071
• DOI: 10.1093/carcin/bgv057
• Languages: English
• ISSNs: 0143-3334

Abstract

Summary: This study demonstrates latent carcinogenic effects of the metabolic programming agent dichloroacetic acid following transient exposure in mice. Our findings highlight the potential for early-life postnatal changes in cell metabolism to alter cancer risk later in life. Abstract: Environmental exposures occurring early in life may have an important influence on cancer risk later in life. Here, we investigated carryover effects of dichloroacetic acid (DCA), a small molecule analog of pyruvate with metabolic programming properties, on age-related incidence of liver cancer. The study followed a stop-exposure/promotion design in which 4-week-old male and female B6C3F1 mice received the following treatments: deionized water alone (dH2 O, control); dH2 O with 0.06% phenobarbital (PB), a mouse liver tumor promoter; or DCA (1.0, 2.0 or 3.5g/l) for 10 weeks followed by dH2 O or PB ( n = 20–30/group/sex). Pathology and molecular assessments were performed at 98 weeks of age. In the absence of PB, early-life exposure to DCA increased the incidence and number of hepatocellular tumors in male and female mice compared with controls. Significant dose trends were observed in both sexes. At the high dose level, 10 weeks of prior DCA treatment induced comparable effects (≥85% tumor incidence and number) to those seen after continuous lifetime exposure. Prior DCA treatment did not enhance or inhibit the carcinogenic effects of PB, induce persistent liver cytotoxicity or preneoplastic changes on histopathology or alter DNA sequence variant profiles within liver tumors compared with controls. Distinct changes in liver messenger RNA and micro RNA profiles associated with prior DCA treatment were not apparent at 98 weeks. Our findings demonstrate that early-life exposure to DCA may be as carcinogenic as life-long exposures, potentially via epigenetic-mediated effects related to cellular metabolism.